HDFC Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

HDFC Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹17.8750
+0.23%
(25 Aug)
AUM
1,936 Cr
TER
0.87%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+15.1%
-7.9%
-7.9%
-7.9%
-8.4%
3Y
NA
+33.4%
+33.4%
+33.4%
+32.5%
5Y
NA
+30.3%
+30.3%
+30.3%
+28.4%
ALL
+36.2%
+11.8%
+11.8%
+11.8%
+16.4%
VOL
14.6%
20.2%
20.2%
20.2%
20.2%
TER
0.9%
0.8%
0.8%
0.8%
0.9%
AUM
₹1,936 Cr
₹5,278 Cr
₹5,278 Cr
₹5,278 Cr
₹1,391 Cr
INFO
2.48
0.58
0.58
0.58
0.81
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
HDFC Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Jul
Top holdings
Sun Pharmaceuticals Industries Ltd
11.0%
Divi's Laboratories Ltd
8.8%
Glenmark Pharmaceuticals Ltd
7.4%
Cipla Ltd
6.3%
Lupin Ltd
6.0%
Ipca Laboratories Ltd
4.4%
Torrent Pharmaceuticals Ltd
3.9%
Krishna Institute of Medical Sciences Ltd
3.8%
Laurus Labs Ltd
3.6%
Eris Lifesciences Ltd Registered Shs
3.5%
Top industry exposure
Healthcare
95.9%
Basic Materials
2.3%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
34%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Dhruv Muchhal
Nikhil Mathur

FAQs